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PURPOSE: Conclusive data on safety of remdesivir in renal
impaired as well as the incidence of liver injury are lacking.
The primary objective of this study is to assess the incidence
of acute kidney injury (AKI) and to trend the liver function
tests (LFTs) during remdesivir treatment and change in eGFR
from baseline to end of remdesivir treatment as well as 48
hours after completion of therapy.

INTRODUCTION: Methicillin-resistant Staphylococcus
aureus (MRSA) infections are associated with prolonged
hospital length of stay and mortality rates up to 20%. Risk
factors for MRSA and presumed type of infection often guide
vancomycin prescribing. This study evaluated the presence of
MRSA risk factors in emergent and critically ill patients who
received vancomycin therapy.

METHODS: This is a retrospective chart review study
including adult Covid19 patients receiving remdesivir with a
baseline eGFR< 30 ml/min per 1.73 m^2 from December
2020 to May 2021. The primary outcome of the study is the
incidence of AKI and hepatic injury. The secondary outcome
is to assess the efficacy of remdesivir defined by oxygen
requirement during therapy.

METHODS: This retrospective study evaluated emergent
and critically ill patients who received vancomycin for at least
24 hours for a presumed infection from 1/2020—3/2020.
Patients were excluded if vancomycin was administered
for surgical prophylaxis. Patients were divided into groups:
MRSA Risk (MRSA-R) vs MRSA No Risk (MRSA-NR).
MRSA risk factors were defined and collected. Culture data
were evaluated 48 hours before and 72 hours after initiation
of vancomycin. SPSS v21.0 was used for analysis.

RESULTS: Seventy-one patients were included in the study.
Average eGFR improved by 30.3% at the immediate end
of remdesivir treatment and by 30.6% at 48 hours after
the end of the treatment (both P< 0.0001). Comparing
to baseline, creatinine at the end of remdesivir treatment
decreased by 20.9% (P< 0.0001), creatinine of 48 hour
after remdesivir treatment decreased by 20.5% (P< 0.0001).
Creatinine clearance increased by 26.6% (P< 0.0001) at
end of treatment and increased by 26.2% (P< 0.0001) by
48 hours after end of treatment. AST average increased by
2.5% at the end of remdesivir treatment (P=0.727). At 48
hours after remdesivir completion, average AST dropped by
15.8% (P=0.021). ALT average increased by 25% (P=0.004)
at the end of remdesivir treatment and increased by 12.0%
(P=0.137) at 48 hours after remdesivir completion. Both
direct and total bilirubin at end of remdesivir treatment as well
as 48 hours later remained stable and did not have significant
changes from baseline (P >0.05). Overall, 38% (27 out of
71 patients) experienced oxygenation improvement shown
by down-titration of oxygen therapy. Fifty-seven percent of
patients received other nephrotoxic medications. The mortality
rate is 33.8%. Fifteen of the 71 patients were admitted into
ICU. Sixty-five percent (46/71) patients were discharged alive
from hospital.
CONCLUSIONS: This study showed that remdesivir use in
renally impaired Covid 19 patients with eGFR< 30 ml/min is
safe and effective. However, large and prospective studies
are needed to validate our findings.
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RESULTS: Of the 1053 emergent and critically ill patients
identified 469 patients were included for analysis (MRSA-R
n=208 vs MRSA-NR n=261). Patients were predominantly
male (58%) with a mean age of 63.8 ±15.9 years. Baseline
vitals were similar between groups. Only 7% of patients had
SBP < 90 mmHg and incidence was similar between groups
(p=0.58). Overall, 56% of patients received vancomycin
without any MRSA risk factors. MRSA was identified on
culture in 40 patients (10% MRSA-R v 7% MRSA-NR,
p=0.27), and MRSA nares screening was positive in 3
patients (0.6%). Of the 208 patients with MRSA-R, the
most common risk factor identified was antibiotic use within
90 days (52%). Of the MRSA-R group, 69% had at least
1 risk factor and 31% had > 2 risks. Vancomycin was more
prescribed in MRSA-R patients in the emergency department
(47% MRSA-R v 25% MRSA-NR, p< 0.001) compared
to MRSA-NR patients in the ICU (19% MRSA-NR vs 6%
MRSA-R, p< 0.001). MRSA-NR patients tended to receive
more vancomycin doses (5.4±4.1 MRSA-NR v 4.7±4.0
MRSA-R, p=0.08). There were no differences in length of
stay (p=0.71) or in-hospital mortality between groups.
CONCLUSIONS: MRSA infections are associated with
negative sequelae. In this study, vancomycin was empirically
prescribed in over half of patients without MRSA risk factors
and MRSA was minimally identified on culture. In supporting
antimicrobial stewardship, additional efforts are needed to
optimize empiric use of vancomycin.
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